EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic surveillance of first- and second-line drug-resistant isolates of Mycobacterium tuberculosis in Peru

David Santos-Lázaro, Aiko N Vigo, Vidia V Cotrina, Sandra Villar, Alexis Medina, Cynthia Julcapoma, Edson Pacheco, Miriam J Alarcón, Zully M Puyén iD

PLOS One · 09.07.2026 · 21 (7) · e0352881

DOI: 10.1371/journal.pone.0352881 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 09.07.2026. Verfasst von David Santos-Lázaro und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Referencia Nacional de Micobacterias, Instituto Nacional de Salud, Lima, Perú. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant, Drug Resistance, Multiple, Bacterial. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PROCIENCIA, Universidad Peruana de Ciencias Aplicadas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB) remains a critical public health crisis in Peru, which bears the highest multidrug-resistant TB (MDR-TB) burden in the Americas. The objective of this study was to conduct a nationwide genetic surveillance of first- and second-line drug-resistant Mycobacterium tuberculosis isolates in Peru to characterize their structural and geographic distribution using a multilocus genotype approach. We analyzed 38,339 valid results from first- and second-line line probe assays (LPA 1L, GenoType MTBDR plus v2; and LPA 2L, GenoType MTBDR sl v2) routinely collected between 2019 and 2022 by the Peruvian National Institute of Health. First-line (G1) and second-line (G2) multilocus genotypes were generated by concatenating specific hybridization banding patterns across resistance-associated loci. Additionally, targeted next-generation sequencing was performed on a stratified proportional sample of 170 isolates exhibiting “inferred” resistance genotypes, defined by a missing wild-type signal without a corresponding mutant probe, to elucidate their underlying mutational profiles. Resistance genotypes were identified in 13.5% and 11.8% of LPA 1L and LPA 2L results, respectively. The genotypic landscape was highly concentrated: 13 dominant G1 genotypes and 19 dominant G2 genotypes accounted for over 85% of their respective resistant cohorts. Structurally, these dominant genotypes mainly carried globally successful, canonical mutations (e.g., katG S315T1, rpoB S450L). Geographically, dominant genotypes were heavily consolidated within the hyper-endemic central coastal axis (Lima, Callao, and Ica) and the Amazonian department of Ucayali, maintaining highly stable temporal frequencies. Conversely, heteroresistance and complex multi-mutational patterns were exclusively restricted to low-frequency rare and orphan genotypes. Targeted sequencing of inferred patterns successfully expanded the national catalog of resistance variants, identifying non-canonical determinants (e.g., inhA g-17t, gyrB T500N) and preventing false-positive resistance calls driven by synonymous mutations. This large-scale mapping demonstrates that Peru’s drug-resistant TB epidemic is characterized by the widespread consolidation of a restricted number of canonical multilocus genotypes. Integrating targeted sequencing with routine molecular screening is essential to resolve unclassified hybridization patterns and optimize epidemiological management in high-burden settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantDrug Resistance, Multiple, BacterialPeruGenotypeHumansAntitubercular AgentsMultilocus Sequence TypingMicrobial Sensitivity TestsMutationHigh-Throughput Nucleotide Sequencing

Substanzen

Antitubercular Agents

Autor:innen und Institutionen

  • Laboratorio de Referencia Nacional de Micobacterias, Instituto Nacional de Salud, Lima, Perú.
  • Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Perú.

ORCID-Profile: Zully M Puyén

Förderung

  • PROCIENCIA
  • Universidad Peruana de Ciencias Aplicadas

Zitieren

APA

Santos-Lázaro, D., Vigo, A. N., Cotrina, V. V., Villar, S., Medina, A., Julcapoma, C., Pacheco, E., Alarcón, M. J., & Puyén, Z. M. (2026). Genetic surveillance of first- and second-line drug-resistant isolates of Mycobacterium tuberculosis in Peru. PLOS One, 21(7), e0352881. https://doi.org/10.1371/journal.pone.0352881

Vancouver

Santos-Lázaro D, Vigo AN, Cotrina VV, Villar S, Medina A, Julcapoma C, et al. Genetic surveillance of first- and second-line drug-resistant isolates of Mycobacterium tuberculosis in Peru. PLOS One. 2026;21(7):e0352881. doi:10.1371/journal.pone.0352881

BibTeX
@article{SantosLzaro2026,
  author = {Santos-Lázaro, David and Vigo, Aiko N and Cotrina, Vidia V and Villar, Sandra and Medina, Alexis and Julcapoma, Cynthia and Pacheco, Edson and Alarcón, Miriam J and Puyén, Zully M},
  title = {Genetic surveillance of first- and second-line drug-resistant isolates of Mycobacterium tuberculosis in Peru},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {7},
  pages = {e0352881},
  doi = {10.1371/journal.pone.0352881}
}
Kostenlos starten →